A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary endpoint while suggesting potential safety advantages.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/head-head-trial-supports-new-treatment-children-multiple-2025a1000qjn?src=rss
Author :
Publish date : 2025-10-03 05:20:00
Copyright for syndicated content belongs to the linked Source.
